Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19Article Published on 2022-11-022022-11-15 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, [키워드] anti-Nucleocapsid IgG anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antigen booster vaccination cellular cellular immunity Cohort Concentration convalescent COVID-19 detectable domain Endemic humoral IFN-γ IgG immune response Immunity Immunoglobulin Immunosuppressed Immunosuppression immunosuppressive individual liver Liver transplantation membrane nucleocapsid Prevalence protective immunity reactivity Receptor binding domain recipient remained retrieved robust SARS-CoV-2 significantly increased Spike protein stimulated T cell T cell response therapy vaccination [DOI] 10.1371/journal.pone.0276929 PMC 바로가기
Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infectionArticle Published on 2022-11-012022-11-15 Journal: Journal of Clinical Virology [Category] SARS, 변종, 진단, 치료기술, [키워드] antibody Antibody neutralization Antibody titre B.1.1.529 BNT162b2 booster Breakthrough infection convalescent CoronaVac COVID-19 detectable dose elicited geometric GMT Immune escape individual Infection less natural infection neutralization neutralizing antibody Neutralizing antibody response of BNT162b2 omicron Omicron, Neutralization plaque reduction neutralization PRNT reduction relative SARS-CoV-2 susceptible Transmissibility vaccinated individual vaccination Vaccine vaccine. Vaccines virus viruses VoC wild- type WT virus [DOI] 10.1016/j.jcv.2022.105273 PMC 바로가기
Potential intestinal infection and faecal-oral transmission of human coronavirusesArticle Published on 2022-11-012022-11-15 Journal: Reviews in Medical Virology [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome circulating close contact common cold coronavirus coronavirus disease COVID-19 described detectable develop Evidence faecal-oral transmission highlight Human human coronavirus human coronaviruses in vitro in vivo Infection intestinal intestinal infection. manifestation MERS MERS-CoV Middle East occur Occurrence Patient Potential proportion provided Respiratory disease respiratory droplet SARS-CoV SARS-CoV-2 shown Spread Symptoms syndrome Transmission Viral RNA [DOI] 10.1002/rmv.2363 PMC 바로가기
Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19Article Published on 2022-11-012022-11-15 Journal: The Journal of Allergy and Clinical Immunology [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome Affect antibodies Asymptomatic autoantibody B-cell function children children with COVID-19 complement Complication complications coronavirus coronavirus disease COVID-19 COVID-19 complications COVID-19 disease Critical detectable develop diagnosed Diagnostic Criteria died disease evaluated Genetic genetic cause genetic diagnosis help hypoxemic IFN signaling IFN-I immune immune response Immunity immunodeficiency Inborn error inborn errors of immunity individual infected with SARS-CoV-2 Infection Inflammasome Inflammatory Inflammatory factor Mild Molecular diagnosis Mortality mortality rate MOST multisystem inflammatory syndrome in children (MIS-C) Mutation Neutralizing Patient patients patients with asymptomatic Pediatric patients plasma Pneumonia primary immunodeficiency. reported SARS-CoV-2 SARS-CoV-2-specific antibodies severe COVID-19 disease syndrome tested Treatment Type I IFN was performed were measured whole-exome sequencing [DOI] 10.1016/j.jaci.2022.09.005 PMC 바로가기
Efficacy of antiseptic mouthrinses against SARS-CoV-2: A prospective randomized placebo-controlled pilot studyArticle Published on 2022-11-012022-11-15 Journal: American journal of otolaryngology [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] Adult patients Affect analyzed baseline chlorhexidine clinical collected COVID-19 detectable Disinfection effective Effectiveness groups Hospitalized hydrogen peroxide individual initial mouth negativity oral oral cavity Oral diseases Oral medicine Oral rinses Patient pilot study Placebo placebo-controlled Povidone‑iodine Public public health Randomized recruited reduced reducing Replication Research Saliva. SARS-CoV-2 SARS-CoV-2 viral load swab specimens the placebo group viral copy number were measured [DOI] 10.1016/j.amjoto.2022.103549 PMC 바로가기
Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasiasArticle Published on 2022-11-012022-11-15 Journal: British Journal of Haematology [Category] 진단, [키워드] age anti-CD38 antibodies antibody Antibody Response Antibody testing antibody titres Antigen binding domain BNT162b2 breadth Cell comparable coronavirus disease correlated COVID-19 COVID-19 vaccination demonstrated detectable dose dyscrasia elicit Genome healthy humoral immune immunization Immunocompromised Immunoglobulin Increasing initial Intervention investigated JNJ-78436735 maturation median mRNA vaccine mRNA-1273 Myeloma of BNT162b2 Patient patient population plasma Population proportion receiving Region response spike-specific T-cell Spike-specific T-cell responses Surface glycoprotein T-cell T-cell receptor T-cell Response TCR tested therapy underlying disease vaccination Vaccines Vaccines. [DOI] 10.1111/bjh.18434 PMC 바로가기
Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunityArticle Published on 2022-11-012022-11-15 Journal: Annals of allergy, asthma & immunology : official [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] antibody Antibody Response Autoimmune clinical trial clinician Combination Comorbidities coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine criteria detectable Diagnosis Evidence Factor healthy controls immune immune dysregulation Immunity immunodeficiency immunogenic individuals literature Messenger RNA Patient performed reactogenicity response Safe Safety SARS-CoV-2 Serious Adverse Events subjects T cell response vaccination Vaccinations Vaccine [DOI] 10.1016/j.anai.2022.06.009 PMC 바로가기
B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patientsArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval Affect anti-CD20 anti-CD20 treatment antibody Antibody Response Antibody titers B cell B cells B-cell B-cell depletion Blood booster cellular response Cohort correlated detectable develop Efficacy Guidance humoral identify IgG^{+} interleukin-13 Logistic regression median memory multiple sclerosis naïve no correlation Odds ratio Patient patients predict predictor Probability recent rituximab S1 domain SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Seroconversion T-cell Response treated Treatment turn vaccination vaccination. vaccine responses [DOI] 10.1111/ene.15492 PMC 바로가기
Longitudinal serologic and viral testing post-SARS-CoV-2 infection and post-receipt of mRNA COVID-19 vaccine in a nursing home cohort-Georgia, October 2020‒April 2021Article Published on 2022-10-272022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] administration Antibody detection Antibody Response binding binding antibody blood collection Card Cohort conducted COVID-19 COVID-19 vaccination COVID-19 vaccine Culture detectable dose evaluate evaluated Final first dose geometric IgA antibodies IgA antibody IgG IgG titer IgM antibodies immune response Immunocompromised Infection longitudinal median age mounted mRNA nasal nine nursing home observation participant polymerase chain positive Post-infection Quantitative questionnaire reverse transcription robust RT-PCR SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2-specific immune response serology specimen subsequent vaccination viral culture [DOI] 10.1371/journal.pone.0275718 PMC 바로가기
Murine Hepatitis Virus, a Biosafety Level 2 Model for SARS-CoV-2, Can Remain Viable on Meat and Meat Packaging Materials for at Least 48 HoursArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 치료기술, [키워드] biosafety Biosafety Level 2 bottleneck BSL2 Can condition conditions contribute coronavirus Coronaviruses COVID-19 case creating detectable determine Evidence facilitate Factor FIVE highest hour hpi hygiene inoculated involved material meat MHV Model murine hepatitis virus notable outbreak packaging material. Particles persistence physical physical distancing plant provide reduction reduction in reservoir resulting SARS-CoV-2 Spread spread of COVID-19 steadily decreased Styrofoam survival tested unpaired t test viability Viable viral infectivity virus [DOI] 10.1128/spectrum.01862-22 PMC 바로가기